InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
InflaRx (NASDAQ:IFRX) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
InflaRx (NASDAQ:IFRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
InflaRx (NASDAQ:IFRX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.